HARP Harpoon Therapeutics Inc

By Ben Glickman

Shares of Harpoon Therapeutics fell Wednesday after the company said AbbVie wouldn't exercise an exclusive license option on one of its treatments.

The stock was down 7.3% to $6.06 after-hours, after falling 4% at Wednesday's close. Shares are down 9.9% this year.

The South San Francisco, Calif.-based immuno-oncology company said that under an agreement set to expire Oct. 12, AbbVie had an exclusive license option on HPN217, a program made by Harpoon which targets B cell maturation antigen.

Harpoon plans to complete the current Phase 1 trial to continue developing the drug.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

September 13, 2023 16:57 ET (20:57 GMT)

Harpoon Therapeutics (NASDAQ:HARP)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024

Harpoon Therapeutics (NASDAQ:HARP)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024